Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified
ConclusionsThese findings support the use of immunohistological subtyping of NSCLC biopsy specimens to select patient-appropriate treatments.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Alimta | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma